BPK-29 |
| Catalog No.GC34502 |
BPK-29 es un ligando especÍfico que interrumpe las interacciones de la proteÍna NR0B1 del receptor nuclear huérfano atÍpico (como RBM45 y SNW1) mediante la modificaciÓn covalente de C274. BPK-29 afecta el crecimiento independiente del anclaje de las células cancerosas mutantes en KEAP1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2143467-62-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BPK-29 is a covalent small molecule that disrupts NR0B1 complexes and impairs the anchorage-independent growth of KEAP1-mutant cancer cells[1].
BPK-29 substantially engages NR0B1 with good overall proteomic selectivity in KEAP1-mutant Non-Small Cell Lung Cancers[1].
[1]. Woodruff TM,et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008 Dec 15;181(12):8727-34.
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *